AUS
NZ
UK
CA
USA
IND
Highlights:
Herwig Janssen appointed as new non-executive chairman of Tryptamine Therapeutics Ltd.
The company advances toward clinical trials using TRP-8803 to treat binge eating disorder.
Strengthened board with Chris Ntoumenopoulos transitioning to executive director.
Tryptamine Therapeutics Ltd (ASX:TRP), a clinical-stage biotechnology company focused on developing psilocin-based therapies, has appointed Herwig Janssen as its new non-executive chairman. This appointment marks a significant shift for the company, as it enters a critical phase in its development, particularly in its clinical programs aimed at treating various conditions like binge eating disorder (BED). Tryptamine’s ticker is listed on the ASX and falls within the biotech sector of the ASX 200.
New Leadership for Clinical Advancement
Janssen brings a wealth of experience to his new role, having spent over four decades in the pharmaceutical industry, including a long tenure at Johnson & Johnson. In his time with J&J, Janssen held significant roles, most notably as vice president in the pharmaceutical division, where he led business development in emerging markets. His leadership helped secure novel technologies, forge licensing agreements, and establish acquisitions, making him a key player in the global healthcare ecosystem.
The appointment comes as Tryptamine is progressing toward initiating world-class clinical trials with its lead drug candidate, TRP-8803. This intravenous formulation of psilocin, a psychedelic compound, is being explored for its therapeutic effects in treating binge eating disorder. Janssen’s prior experience in scaling businesses and his expertise in navigating international healthcare markets are expected to play a key role in guiding Tryptamine through its clinical and commercial milestones.
Board Changes to Strengthen Leadership
Along with the appointment of Janssen, Tryptamine Therapeutics has also announced changes within its board of directors. Chris Ntoumenopoulos, who has served as a non-executive director since May 2024, will transition into the role of executive director. Ntoumenopoulos brings extensive biotech experience, having held senior roles at companies such as Race Oncology and ResApp Health. His move to an executive role reflects the company’s strategy to further enhance its leadership team as it prepares for critical clinical trials and efforts in the commercialization of its therapies.
Tryptamine’s CEO, Jason Carroll, expressed confidence in the new leadership lineup. According to Carroll, both Janssen and Ntoumenopoulos bring significant experience that will help guide the company as it works to advance its clinical programs and navigate the emerging psychedelics-based therapeutic landscape.
A Focus on Psilocin-Based Therapies
Tryptamine Therapeutics is focused on utilizing psilocin, a psychoactive compound derived from psychedelic mushrooms, to develop treatments for several medical conditions. The company is currently advancing clinical trials for its psilocin-based therapies, targeting not only binge eating disorder but also conditions such as fibromyalgia and irritable bowel syndrome. These treatments fall within a broader shift toward psychedelics in modern medicine, which has gained increasing attention for its potential in treating mental health and chronic conditions.
The leadership changes, including the appointment of Janssen and the transition of Ntoumenopoulos, are aligned with Tryptamine’s strategic focus on strengthening its position within the rapidly evolving psychedelics-based therapeutics space. As the company moves forward with its clinical trials, the expertise of the new board members is seen as crucial in securing its success.
Tryptamine Therapeutics continues to work toward its clinical and commercial milestones as it seeks to make significant strides in developing innovative therapies that may have the potential to improve patient outcomes in a variety of therapeutic areas.
